Could an eye injection ease thyroid eye disease? small trial tests safety

NCT ID NCT04311606

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 2 trial tested whether injections of aflibercept, a drug that blocks abnormal blood vessel growth, are safe for people with active thyroid eye disease. Eleven adults received three injections over a month, with or without hyaluronidase to help spread the drug. The main goal was to check for side effects, not to measure how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
aflibercept (a drug that blocks blood vessel growth), given with either saline or hyaluronidase
What this could lead to
If it works, this could point toward a new treatment option for thyroid eye disease that reduces inflammation and eye bulging.
What could go wrong
This is a very early, small Phase 2 trial with only 11 people, focused mainly on safety. It may not show clear benefit, and aflibercept injections near the eye carry risks like infection or vision changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mass Eye and Ear

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.